Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13301
- By:
- Publication type:
- Article
Works matching IS 09607722 AND DT 2022 AND VI 55 AND IP 8
Results: 14
1
2
Quality matters: International standards for biobanking.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13282
- Publication type:
- Article
3
An allied reprogramming, selection, expansion and differentiation platform for creating hiPSC on microcarriers.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13256
- By:
- Publication type:
- Article
4
Scalable manufacturing of clinical‐grade differentiated cardiomyocytes derived from human‐induced pluripotent stem cells for regenerative therapy.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13248
- By:
- Publication type:
- Article
5
Advances in hPSC expansion towards therapeutic entities: A review.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13247
- By:
- Publication type:
- Article
6
Knowledge graphs of ethical concerns of cerebral organoids.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13239
- By:
- Publication type:
- Article
7
Human pluripotent stem cell registry: Operations, role and current directions.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13238
- By:
- Publication type:
- Article
8
Manufacturing clinical‐grade human induced pluripotent stem cell‐derived beta cells for diabetes treatment.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13232
- By:
- Publication type:
- Article
9
Selection of O‐negative induced pluripotent stem cell clones for high‐density red blood cell production in a scalable perfusion bioreactor system.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13218
- By:
- Publication type:
- Article
10
Development and regulation of stem cell‐based therapies in China.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13217
- By:
- Publication type:
- Article
11
Translating stem cell research into development of cellular drugs—a perspective from manufacture of stem cell products and CMC considerations.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13203
- By:
- Publication type:
- Article
12
Re‐defining and tackling the emerging challenges in stem cell research and translation: A report of the 10th CSSCR annual meeting.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13186
- By:
- Publication type:
- Article
13
Issue Information.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.13067
- Publication type:
- Article
14
Featured Cover.
- Published in:
- Cell Proliferation, 2022, v. 55, n. 8, p. 1, doi. 10.1111/cpr.12983
- By:
- Publication type:
- Article